Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cook Incorporated Receives FDA Clearance For Investigational Use Of Zilver Vascular Stent.


Business Editors, Health & Medical Writers

BLOOMINGTON, Ind.--(BW HealthWire)--Aug. 15, 2002

Cook Incorporated may begin investigational use of its new vascular stent in human patients under an investigational device exemption An Investigational Device Exemption (IDE) allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application or a Premarket Notification [510(k)] submission to Food and  granted by the U.S. Food and Drug Administration. The company received permission to use its Zilver(R) Vascular Stent System to treat symptomatic vascular disease of the iliac arteries on 20 patients at four medical institutions initially, with plans to expand the study eventually to 150 patients at up to 20 investigational sites.

"Coronary stents have been among the most dramatically successful medical device innovations in the last decade, and we believe the opportunity for vascular stents is at least as exciting," explained Kem Hawkins, president of Cook Incorporated. "Cook leadership in stents and other technologies to treat vascular disease in the peripheral arteries Peripheral Arteries are the arteries (specifically arterioles and capillaries) which are furthest from the heart (mouth, hands, and feet). In some cases blockages in the peripheral arteries may be treated with catheterization and balloon dilatation instead of surgery.  further enhances our position as a pioneer in innovative medical solutions for patients worldwide."

The Zilver Stent is a self-expanding nitinol design incorporating Cook's Z-Stent cell design for optimal strength while maintaining a strong, equally distributed radial force throughout the stented area of the artery. The Zilver design displays excellent kink resistance while conforming to tortuous anatomy. With its multiple gold radiopaque ra·di·o·paque
adj.
Relatively impenetrable by x-rays or other forms of radiation.


radiopaque (rā´dēōpāk´),
adj
 markers at each end to enhance visibility under fluoroscopy fluoroscopy /flu·o·ros·co·py/ (fldbobr-ros´kah-pe) examination by means of the fluoroscope.

fluo·ros·co·py
n.
Examination by means of a fluoroscope. Also called radioscopy.
 and zero percent foreshortening foreshortening,
n See distortion, vertical.
 during deployment, the clinician can place the Zilver stent with great precision.

With international headquarters in Bloomington, Ind., privately held COOK(R) (www.cookgroup.com/) is a leading designer, manufacturer and global distributor of minimally invasive medical device technology for diagnostic and therapeutic procedures. Since its founding in 1963, Cook has created innovative technologies for stents and stent-grafts, catheters, wire guides, introducer needles and sheaths, embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun)
1. the process or condition of becoming an embolus.

2. therapeutic introduction of a substance into a vessel in order to occlude it.
 coils, tissue-engineered medical biomaterials, vena cava filters Vena Cava Filter Definition

A vena cava filter is a device inserted into a major vein to prevent a blood clot from entering the lungs.
Purpose
, implanted cardiac lead extraction equipment and other minimally invasive medical devices.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 15, 2002
Words:295
Previous Article:Kaiser Permanente Appoints Mary Ann Thode President, Northern California Region.
Next Article:AmerenUE's Senior Secured Notes Rated 'AA-' By Fitch Ratings.



Related Articles
Guidant and Cook Announce Submission of FDA Filing to Begin U.S. Drug-Coated Stent Trial.
Guidant and Cook Announce FDA Approval To Begin U.S. Clinical Trial With Paclitaxel-Coated Stent; First U.S. Patient Treated in Pivotal Clinical...
Cook Incorporated To Begin First U.S. Clinical Trial Of A Drug-Eluting Non-Coronary Stent.
Cook and Angiotech Restructure License Agreement; Cook to Focus on Developing Paclitaxel-Eluting Medical Devices for Peripheral -- Non-Coronary --...
First U.S. Drug-Eluting Stent Trial To Treat Peripheral Arterial Disease Enrolls First Patient At Stanford University Medical Center.
Cook to Begin First International Trial of a Paclitaxel-Eluting Stent for Peripheral Artery Disease; New Treatment Could Benefit Millions Who Suffer...
News from Cook: Two Patients Treated in First International Case Testing Drug-Eluting Stents To Treat Peripheral Arterial Disease.
Cook Launches Web Site for Patients Seeking Information About Peripheral Arterial Disease; Site Provides Information About Drug-Coated Stent in...
Cook Zilver Stent Receives FDA Approval for Vascular Use.
First International Trial of Drug-Eluting Peripheral Artery Stent Results Encouraging.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles